• Users Online: 89
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW
Year : 2017  |  Volume : 2  |  Issue : 1  |  Page : 7-11

Impact of incretin-related agents on endothelial cell function


1 Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
2 Manda Memorial Hospital, Sapporo, Japan
3 Kurihara Clinic, Sapporo, Japan
4 Aoki Clinic, Sapporo, Japan
5 The membership of the SAIS Study Group is provided in the Acknowledgements

Correspondence Address:
Hideaki Miyoshi
Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo
Japan
Login to access the Email id

Source of Support: This work was supported by The Japan Diabetes Foundation Inc. and The Waksman Foundation of Japan Inc. , Conflict of Interest: None


DOI: 10.4103/2542-3975.202726

Rights and Permissions

Incretin-related drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, have been clinically available and widely used to treat patients with type 2 diabetes mellitus. Accumulating evidence indicates that these agents exert glycemic control and have various other favorable effects, including prevention of atherosclerosis. It is important to assess and manage early-phase atherosclerosis, but whether diabetic therapeutics including incretin-related drugs improve or maintain vascular endothelial cell function has not been fully determined. We previously published prospective clinical trials focused on flow-mediated dilation in patients with type 2 diabetes, who did not have severe atherosclerosis, using two different incretin-related drugs: a DPP-4 inhibitor and a GLP-1 analogue. These trials showed that these therapeutic agents did not improve endothelial cell function. In this article, we discuss how incretin-related drugs contribute, if at all, to vascular endothelial cell function, atherosclerosis, and beta-cell function, based on our clinical trials and previous evidence.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed389    
    Printed36    
    Emailed0    
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal